Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | ALDH3A1 | P30838 | 4/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3986887 | 1.00 | ALDH1A1 (0.59) | ALDH1A1ALDH3A1CA1CA2MAPT | |
| SCHEMBL490225 | 0.90 | CA1 (0.55) | ALDH1A1ALDH3A1CA1CA2MAPT | |
| SCHEMBL490223 | 0.90 | CA1 (0.55) | ALDH1A1ALDH3A1CA1CA2MAPT | |
| SCHEMBL685083 | 0.89 | CA1 (0.57) | ALDH1A1ALDH3A1CA1CA2MAPT | |
| SCHEMBL3911160 | 0.87 | ALDH3A1 (0.59) | ALDH1A1ALDH3A1CA1CA2MAPT | |
| SCHEMBL3911162 | 0.87 | ALDH3A1 (0.59) | ALDH1A1ALDH3A1CA1CA2MAPT | |
| SCHEMBL3911110 | 0.78 | KDR (0.48) | ALDH1A1MAPTKDM4EKDRRET | |
| SCHEMBL3911113 | 0.78 | KDR (0.48) | ALDH1A1MAPTKDM4EKDRRET | |
| SCHEMBL4624387 | 0.75 | ALDH3A1 (1.00) | ALDH1A1ALDH3A1CA1CA2MAPT | |
| SCHEMBL3921388 | 0.72 | ALDH1A1 (0.57) | ALDH1A1ALDH3A1CA1CA2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102509-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | ALLERGAN, INC. | 2004-05-27 | — | — | US | claimed |
| US-6699863-B1 | REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION. | ALLERGAN, INC. | 2004-03-02 | — | — | US | claimed |
| US-7531665-B2 | Kinase inhibitors for the treatment of disease | ALLERGAN, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-20070213403-A1 | TAMOXIFEN RESPONSE IN PRE-AND POSTMENOPAUSAL BREAST CANCER PATIENTS | FORSKARPATENT I SYD AB (SE) | 2007-09-13 | — | — | US | disclosed |
| EP-1773309-A1 | TAMOXIFEN RESPONSE IN PRE-AND POSTMENOPAUSAL BREAST CANCER PATIENTS | Forskarpatent i Syd AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006004545-A1 | TAMOXIFEN RESPONSE IN PRE-AND POSTMENOPAUSAL BREAST CANCER PATIENTS | FORSKARPATENT I SYD AB (SE) | 2006-01-12 | — | — | WO | disclosed |
| US-20040198802-A1 | Kinase inhibitors for the treatment of disease | ALLERGAN, INC. | 2004-10-07 | — | — | US | disclosed |
| US-6747025-B1 | TREATING DISEASES RELATED TO UNREGULATED TYROSINE KINASE SIGNAL TRANSDUCTION; ANTIPROLIFERATIVE AGENTS | ALLERGAN, INC. | 2004-06-08 | — | — | US | disclosed |
| US-20040102509-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | ALLERGAN, INC. | 2004-05-27 | — | — | US | disclosed |
| US-6699863-B1 | REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION. | ALLERGAN, INC. | 2004-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198802-A1 | Kinase inhibitors for the treatment of disease | ABL1, ERBB2, LCK | ALDH1A1 2496/4885ALDH3A1 3352/4885CA1 3591/4885 |
| US-20040102509-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | ABL1, ERBB2, LCK | ALDH1A1 2496/4885ALDH3A1 3352/4885CA1 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.